Abstract

Results Antibiotics (n=12) were the most common offending drugs, followed by non-steroidal anti-inflammatory drugs (n=8), anti-rheumatic drugs (n=2) and Chinese herbs (n=2). Hypertension (34.4%, n=11) and diabetes (21.9%, n=7) were the most common pre-existing conditions. Hepatitis B virus infection, cerebrovascular diseases and cardiovascular diseases pre-existed in 15.6% (n=5), 12.5% (n=4) and 12.5% (n=4) of the 32 patients, respectively. TEN showed higher incidence in the patients with HBV infection. All 32 patients were treated initially with systemic corticosteroids ranging from 50 mg to 150 mg daily. Sixteen patients were treated with combined IVIG (400 mg/kg/day, for 5 days). Twenty-nine patients were cured without or with different sequelae. The mortality rate was 9.38% (n=3). The application of IVIG reduced the estimated mortality of TEN to 17%. Delayed use of IVIG, elevated level of urea nitrogen and early onset of the rashes after taking offensive drugs were associated with the mortality of TEN.

Highlights

  • Toxic epidermal necrolysis (TEN), the most severe drug reaction, has been reported to be associated with considerable mortality rate

  • We retrospectively studied 32 patients with TEN in a Chinese tertiary medical center between July 1, 2008 and June 30, 2013 to evaluate the clinical manifestations, laboratory tests, treatment of TEN and prognostic factors for the mortality of TEN

  • The application of intravenous immunoglobulin (IVIG) reduced the estimated mortality of TEN to 17%

Read more

Summary

Introduction

Toxic epidermal necrolysis (TEN), the most severe drug reaction, has been reported to be associated with considerable mortality rate. Treatment and outcome of toxic epidermal necrolysis in 32 Chinese patients: a hospitalbased study From 6th Drug Hypersensitivity Meeting (DHM 6) Bern, Switzerland. Background Toxic epidermal necrolysis (TEN), the most severe drug reaction, has been reported to be associated with considerable mortality rate.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call